July 01, 2010
Phase 2a study of MP4OX for treatment of hemorrhagic shockSangart, Inc. announced that enrollment was completed in a Phase 2a study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. This multi-center, randomized, double-blind, controlled clinical trial enrolled 51 patients experiencing trauma-induced severe hemorrhagic shock at 12 international clinical sites to investigate improved oxygenation of organs and tissues. The primary objective of the study was to measure reduction in lactate levels after infusion of MP4OX.
MP4OX is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries.
For more information call (858) 450-2400 or visit www.sangart.com.